BTN3A1 Protein, Human, Recombinant

BTN3A1 Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 24.16 kDa and the accession number is NP_919423.1.

Pack Size	Availability	Price/USD	Quantity
100 μg	5 days	$ 801.00
1 mg	5 days	$ 5,220.00

Pack Size

Availability

Price/USD

Quantity

100 μg

5 days

$ 801.00

1 mg

5 days

$ 5,220.00

Description

BTN3A1 Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 24.16 kDa and the accession number is NP_919423.1.

Species	Human
Expression System	HEK293 Cells
Tag	Tag Free
Accession Number	NP_919423.1
Synonyms	BTF5, CD277, BTN3.1, BT3.1, butyrophilin subfamily 3 member A1
Construction	Human BTN3A1 (NP_919423.1) (Met1-Gly254)
Protein Purity	≥ 90 % as determined by SDS-PAGE. ≥ 90 % as determined by SEC-HPLC.
Molecular Weight	24.16 kDa (predicted)

Endotoxin	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
Reconstitution	A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.
Stability & Storage	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at-80℃. For reconstituted proteinsolutions, the solution can be stored at -20°c to -80'c for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	In general, Lyophilized powders are shipping with blue ice.
Research Background	BTN3A1 has the structure of a type I receptor of the Ig superfamily and is part of a family of seven BTN receptors encoded by genes in the MHC. BTN molecules are composed of two Ig domains (IgV, IgC2), a single transmembrane domain, and a large carboxyl-terminal domain termed B3.2 (or PRYSPRY) located in the cell cytoplasm. There are three human BTN3A loci, BTN3A1, BTN3A2, and BTN3A3, and clear orthologs of BTN3A molecules, now called CD277, are absent from the mouse genome. Despite its similarity to B7 molecules, BTN3A1 was proposed to act not as a coreceptor or costimulatory molecule, but rather to directly present pAg to the γδ TCR in a manner analogous to MHC-restricted peptide presentation. However, this model of BTN3A1 function has been challenged by conflicting data, which show pAg binding to a positively charged pocket in the cytosolic B3.2 domain, and that BTN3A1 does not directly engage the γδ TCR. This contradictory picture has emerged as a result of the complexity of the system and in particular by the use of endogenous and exogenous routes of Ag delivery in in vitro assays.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy